Form 4: Xilio Therapeutics Director Acquires 50,000 Stock Options

James Samuel Shannon, a director of Xilio Therapeutics, acquired 50,000 stock options on June 13, 2024, according to a Form 4 filing with the SEC.

Summary

• James Samuel Shannon, a director at Xilio Therapeutics, Inc. (XLO), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 13, 2024, where Shannon acquired 50,000 stock options.
• The exercise price of these options is $1.05.
• The options vest in three equal installments on June 13, 2025, June 13, 2026, and June 13, 2027, contingent upon continued service to Xilio Therapeutics.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (stock option grant) to a director, which can be interpreted as a sign of confidence in the company, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options (June 13, 2025, June 13, 2026, and June 13, 2027) suggests a multi-year commitment from the director to the company.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This particular filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Xilio Therapeutics.
• Comparable companies such as Arcus Biosciences or Gritstone Bio also utilize stock options to incentivize their leadership teams.
• The vesting schedule of three years is also typical in the industry, aligning the director's interests with the long-term performance of the company.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates